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ABSTRACT 
NMNAT2 is an endogenous axon maintenance factor that preserves axon health by blocking 
Wallerian-like axon degeneration. Mice lacking NMNAT2 die at birth with severe axon defects 
in both the PNS and CNS so a complete absence of NMNAT2 in humans is likely to be 
similarly harmful, but probably rare. However, there is evidence of widespread natural 
variation in human NMNAT2 mRNA expression so it is important to establish whether reduced 
levels of NMNAT2 have consequences that impact health. Whilst mice that express reduced 
levels of NMNAT2, either those heterozygous for a silenced Nmnat2 allele, or compound 
heterozygous for one silenced and one partially silenced Nmnat2 allele, remain overtly normal 
into old age, we now report that Nmnat2 compound heterozygote mice present with early and 
age-dependent peripheral nerve axon defects. Compound heterozygote mice already have 
reduced numbers of myelinated sensory axons at 1.5 months and lose more axons, likely motor 
axons, between 18 and 24 months and, crucially, these changes correlate with early temperature 
insensitivity and a later-onset decline in motor performance. Slower neurite outgrowth and 
increased sensitivity to axonal stress are also evident in primary cultures of Nmnat2 compound 
heterozygote superior cervical ganglion neurons. These data reveal that reducing NMNAT2 
levels below a particular threshold compromises the development of peripheral axons and 
increases their vulnerability to stresses. We discuss the implications for human neurological 
phenotypes where axons are longer and have to be maintained over a much longer lifespan.  
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INTRODUCTION 
Axon degeneration is an early pathology in several neurodegenerative disorders and in many 
cases the underlying mechanism is related to injury-induced (Wallerian) degeneration (1). 
Wallerian degeneration proceeds via a conserved pathway in which nicotinamide 
mononucleotide adenylyltransferase (NMNAT) activity, a central activity during NAD 
biosynthesis, acts as a key regulator (1). Of the three NMNAT isoforms in mammals, 
NMNAT2 appears to have the most influence over axon survival under physiological 
conditions as only depletion of this isoform causes a primary axonal phenotype either in vitro 
or in vivo (2-6). 
 Homozygous Nmnat2 gene trap mice lacking detectable NMNAT2 have a severe axon 
outgrowth defect resulting in widespread axon truncation in both the PNS and CNS that is 
incompatible with post-natal survival (3, 5). Importantly, the underlying defect involves a 
Wallerian-like mechanism as three unrelated genetic manipulations that strongly delay 
Wallerian degeneration - the slow Wallerian degeneration (WldS) mutation, knockout of the 
Sarm1 gene encoding the pro-degenerative sterile alpha and TIR motif-containing protein 1 
(SARM1), and a bacterial nicotinamide mononucleotide (NMN) deamidase transgene - all 
improve axon outgrowth and rescue lethality (3, 7, 8). Remarkably, mice rescued by Sarm1 
deletion remain overtly normal up to 2 years (9). 
 Single nucleotide polymorphisms (SNPs) within the NMNAT2 gene show genome-wide 
significant association with human cognition (10) and a positive correlation between cognition 
and NMNAT2 mRNA levels has been identified (11). Reduced NMNAT2 mRNA levels are also 
seen in Parkinson's, Alzheimer's and Huntington's disease patients (11, 12) and Nmnat2 mRNA 
levels are reduced prior to the onset of pathological changes in a mouse model of tauopathy 
(13). These observations suggest that constitutively low or declining expression of this key 
regulator of axon health might contribute to clinical and sub-clinical phenotypes. Crucially, 
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NMNAT2 mRNA levels appear to vary widely between individuals in the human population 
(11), so a better understanding of how reduced (but not absent) NMNAT2 expression influences 
axon survival, either constitutively or in response to neurodegenerative stresses, is needed. 
 Mice heterozygous for a silenced Nmnat2 allele are viable (3, 5) and, other than reduced 
expression of synaptic proteins in the hippocampus (11) and cortical neurons that are modestly 
more sensitive to the chemotherapeutic agent vincristine in culture (14), they otherwise appear 
superficially normal up to at least 12 months of age (3, 14). In fact, PNS and CNS axon 
outgrowth and several baseline or induced behaviors, including their response to vincristine in 
vivo, are unaltered (3, 5, 14). Thus, current observations suggest a halving of NMNAT2 
expression has relatively limited effects on neural development and maintenance in mice. 
However, by studying compound heterozygous mice with one silenced and one partially 
silenced Nmnat2 allele (3), we now show that sub-heterozygous Nmnat2 expression results in 
the absence and/or loss of specific peripheral nerve axon populations and that this correlates 
with changes to baseline responses in specific behavioral tests. Outgrowth of neurites and their 
resistance to vincristine toxicity are also compromised in primary cultures of superior cervical 
ganglion (SCG) neurons. The possibility that the development of much longer human axons 
and their ability to cope with neurodegenerative stresses, including normal ageing over a much 
greater lifespan, could be similarly affected by comparably low NMNAT2 expression will have 
important implications in relation to disease susceptibility and clinical outcomes.  
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RESULTS 
Mice with low level Nmnat2 expression are viable and overtly normal 
We previously crossed mice heterozygous for two distinct Nmnat2 gene trap alleles with 
different degrees of gene silencing, Nmnat2gtE and Nmnat2gtBay, to generate mice with graded 
levels of Nmnat2 mRNA and NMNAT2 protein expression (3). Whilst a gene trap cassette is 
located in the large first intron of the Nmnat2 gene in each case, the Nmnat2gtE allele appears 
to be completely silenced (3) whereas the Nmnat2gtBay allele is only partially silenced and 
retains ~50% of normal expression (15). Mice of all four genotypes produced from these 
crosses, including Nmnat2gtBay/gtE compound heterozygotes with the lowest, sub-heterozygous 
levels of expression, were reported to be viable and overtly normal up to 12 months of age (3). 
 We now confirm that genotype ratios for offspring of these crosses are not significantly 
different from that expected (Fig. 1A), that there is no significant difference in body weight 
between genotypes at either 6 or 24 months (Fig. 1B), and that no genotype can be 
distinguished from littermates based on appearance or home cage behavior. Whereas Nmnat2 
mRNA levels in the brains of newborn Nmnat2+/gtE single heterozygote pups or late-stage 
embryos are consistently almost exactly 50% of that in wild-types (3, 8), we found levels to be 
around 60% in 6 month old mice (Fig. 1C). This could reflect a change in splicing that modestly 
alters the efficiency of Nmnat2gtE gene trap silencing and/or compensatory up-regulation or 
stabilization of Nmnat2 mRNA expressed from the wild-type allele. Nevertheless, the amount 
of Nmnat2 mRNA in the brains of adult Nmnat2gtBay/gtE compound heterozygote mice, at around 
30% of wild-type levels, is still well below a true heterozygous level of 50% (Fig. 1C). These 
findings confirm that Nmnat2 expression can be reduced to sub-heterozygous levels in mice 
without compromising long-term viability and without any effect on overt morphology or 
behavior. 
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Nmnat2 compound heterozygote mice have an early deficiency of myelinated sensory 
axons with later-onset motor axon changes 
Given that NMNAT2 is critically required for axon development and survival (3, 5), we 
assessed whether there was any loss of peripheral axons in either Nmnat2+/gtE single 
heterozygote or Nmnat2gtBay/gtE compound heterozygote mice compared to wild-types. We 
initially performed counts of myelinated axons in the tibial nerve, at mid-calf level, of 6 and 
24 month old mice. The number of myelinated axons in Nmnat2+/gtE single heterozygotes was 
comparable to wild-types at both ages with no evidence of substantial axon loss between 6 and 
24 months in either (Fig. 2A). In contrast, we found that Nmnat2gtBay/gtE compound 
heterozygote mice already had around 25% fewer myelinated tibial nerve axons at 6 months 
and showed a further reduction at 24 months (Fig. 2A). An extended analysis, specifically in 
nerves from Nmnat2gtBay/gtE and wild-type mice at 1.5 and 18 months, revealed that a reduction 
in axon numbers in Nmnat2gtBay/gtE nerves was already evident at 1.5 months and remained 
stable up to 18 months, with the additional axon loss occurring after this age (Fig. 2B). The 
relative deficiency of axons in Nmnat2gtBay/gtE nerves at each age was matched by a proportional 
reduction in nerve cross-sectional area such that axon density remained similar to wild-types 
at each age (Fig. 2C and 2D). These observations are consistent with a constitutive deficiency, 
or a very early loss, of myelinated tibial nerve axons in Nmnat2gtBay/gtE mice followed by some 
additional, slowly-progressing loss in old age. 
 We next assessed numbers of myelinated axons in dorsal and ventral roots close to the L3 
dorsal root ganglion (DRG) of 6 and 24 month wild-type and Nmnat2gtBay/gtE mice. L3 roots 
contribute a significant proportion of axons to the tibial nerve in mice (16) and were thus used 
to determine whether sensory or motor axons are missing from Nmnat2gtBay/gtE tibial nerves at 
either age. We found that there were around 30% fewer myelinated axons in the L3 dorsal roots 
of Nmnat2gtBay/gtE compound heterozygotes compared to wild-types at 6 months, with no further 
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reduction at 24 months (Fig. 3A). Measurement of axon diameters revealed a specific reduction 
in small diameter (1-3 µm) myelinated axons, presumably A fibers, in the Nmnat2gtBay/gtE roots 
(Fig. 3B). Crucially, the remaining axons appeared morphologically normal, even at 24 months 
(Fig. 3C). In contrast, myelinated motor axon numbers and morphology in Nmnat2gtBay/gtE L3 
ventral roots were comparable to wild-types at 6 months, but by 24 months we observed a 
substantial increase in axons with unusually thin myelin sheaths relative to axon diameter, 
resembling regenerating fibers, counteracting a proportionately smaller reduction in the 
numbers of axons with normal morphology (Fig. 3D, 3E and 3F). The number of axons with 
abnormal myelin (invaginations, evaginations or wide incisures) was not altered (Fig. 3F). 
Intriguingly, this resulted in an overall increase in the total number of myelinated axons in the 
Nmnat2gtBay/gtE ventral roots (Fig. 3D). A plausible explanation for these observations is that 
slowly progressing motor axon loss in old Nmnat2gtBay/gtE mice triggers a robust regeneration 
response with some axonal sprouting. 
 Together, these results suggest that an early deficiency of myelinated axons in 
Nmnat2gtBay/gtE compound heterozygote tibial nerve is due to a constitutive deficiency, or very 
early loss, of small caliber myelinated sensory axons, whereas a later, age-dependent loss of 
myelinated axons in tibial nerve from 18 months onwards probably reflects motor axon loss. 
Putative regenerating axons that are evident in L3 ventral roots were not seen in tibial nerve at 
mid-calf level suggesting they do not extend that far. 
 
Early deficiency in thermal discrimination and age-dependent decline in Rotarod 
performance in Nmnat2gtBay/gtE compound heterozygote mice 
We next performed a series of behavioral tests to assess whether any baseline sensory and 
motor functions, not apparent from normal cage activity, are altered in Nmnat2gtBay/gtE 
compound heterozygote mice as a result of the constitutive and age-dependent reductions in 
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axon numbers. Three main tests were employed: the two-plate thermal place preference test, 
which assesses thermal perception; the plantar aesthesiometer, which assesses mechanical 
sensitivity in the hindpaw; and the accelerating Rotarod, which assesses motor function and 
proprioception. All three tests provide objective measures of behavior.  
 Interestingly, using the same groups of 6-9 month male mice, we saw no differences 
between genotypes in the plantar aesthesiometer test, but did find altered sensitivity to non-
harmful hot and cold temperatures in the two-plate thermal place preference test. Wild-type, 
Nmnat2+/gtE single heterozygote and Nmnat2gtBay/gtE compound heterozygote mice all 
responded similarly to increasing probe force in the plantar aesthesiometer test, either in terms 
of the average force at which hindpaw withdrawal occurred or the average latency to 
withdrawal (Fig. 4A). In contrast, Nmnat2gtBay/gtE compound heterozygotes showed 
substantially reduced avoidance of cool (15°C) and warm (40°C and 45°C) test plates 
compared to wild-types in the two-plate thermal place preference test (control plate set at a 
preferred 30C) (Fig. 4B). At a more noxious cold temperature (5°C) there was a similar trend 
that was not significant in these experiments (Fig. 4B). Nmnat2+/gtE single heterozygote mice, 
on the other hand, did not show any statistically-significant differences compared to wild-types 
for any test temperature, although avoidance of the 15°C and 40°C test plates was intermediate 
between wild-type and Nmnat2gtBay/gtE mice with a large degree of variability within the group 
(Fig. 4B). 
 Differences between genotypes were also seen on the accelerating Rotarod. Groups of 
female mice were longitudinally tested every three months between 6 and 24 months of age. 
No age-related change in latency to fall was seen for any genotype up to 18 months (Fig. 4C) 
and differences between genotypes did not reach statistical significance up to this age (Fig. 
4D). However, the performance of Nmnat2gtBay/gtE compound heterozygote mice declined from 
18 months onwards (Fig. 4C), such that by 24 months there was a statistically-significant 
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reduction in their latency to fall compared to wild-types (Fig. 4D). Notably, this decline in 
Rotarod performance was not accompanied by a clasping phenotype when Nmnat2gtBay/gtE mice 
were suspended by their tails suggesting normal proprioception (data not shown). No age-
dependent decline in performance was seen for Nmnat2+/gtE single heterozygote mice (Fig. 4C), 
although latency to fall was consistently slightly reduced compared to wild-types for this 
particular group (Fig. 4D). Average body weight for each genotype was comparable at all ages 
ruling it out as a confounding factor (Fig. 4E). 
 Notably, an early defect in thermal perception and later, progressive deterioration of motor 
performance from 18 months onwards in Nmnat2gtBay/gtE mice is broadly consistent with the 
constitutive or early loss of peripheral sensory axons and the later-onset motor axon changes 
seen in Nmnat2gtBay/gtE L3 dorsal and ventral roots and tibial nerve. 
 
Sub-heterozygous levels of NMNAT2 alter outgrowth and vulnerability of SCG neurites 
An absence of NMNAT2 severely restricts neurite outgrowth in primary neuronal cultures, 
whereas a halving of NMNAT2 expression has no obvious effect (3). We therefore investigated 
whether sub-heterozygous levels of Nmnat2 expression might compromise neurite outgrowth 
in DRG or superior cervical ganglion (SCG) primary explant cultures. Surprisingly, no 
differences in neurite outgrowth were seen between genotypes in explant cultures of embryonic 
day 13.5-14.5 DRGs (data not shown), but we did find that the rate of neurite outgrowth in 
postnatal day 0-2 Nmnat2gtBay/gtE compound heterozygote SCG explant cultures was reduced 
relative to both wild-types and Nmnat2+/gtE single heterozygotes (Fig. 5A and 5B). Outgrowth 
slowed from 2-3 days in vitro (DIV2-3) such that by DIV7 Nmnat2gtBay/gtE SCG neurites were 
on average around 20 percent shorter (Fig. 5B). Thus, sub-heterozygous levels of Nmnat2 
expression can compromise neurite outgrowth in some neuron types.  
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 The late loss of motor axons in Nmnat2gtBay/gtE compound heterozygote nerves also 
suggests that axons with reduced levels of NMNAT2 are more sensitive to natural, age-
associated stresses. We therefore tested whether we could artificially replicate this increased 
sensitivity by assessing the effects of vincristine specifically on neurite health in primary SCG 
explant cultures. Vincristine triggers Wallerian-like degeneration of neurites of peripheral 
neurons in primary culture (17-19) likely by inhibiting fast axonal transport (20). We identified 
1 nM to be the lowest single dose of vincristine that did not reproducibly trigger neurite 
degeneration for any genotype (data not shown), but found that daily treatment with 1 nM 
vincristine produced a very slowly progressing degeneration of distal neurites, primarily 
characterized by blebbing, that was accelerated specifically in the Nmnat2gtBay/gtE compound 
heterozygote cultures (Fig. 5C and 5D). Thus, Nmnat2gtBay/gtE SCG neurites appear more 
sensitive to vincristine-induced degeneration than either wild-type or Nmnat2+/gtE neurites. 
Importantly, this effect on neurites is probably distinct from the loss of neuronal viability 
associated with high dose vincristine seen in cortical cultures where single heterozygote 
Nmnat2+/gtE neurons are slightly more sensitive than wild-types (14). 
 Finally, given the prediction that rapid NMNAT2 loss in transected axons acts as a critical, 
early initiating trigger for degeneration (4), we tested whether different steady-state levels of 
NMNAT2 influence the timing of Wallerian degeneration in SCG explant cultures. 
Intriguingly, the latent phase between injury and the onset of frank degeneration was 
comparable between cut wild-type and Nmnat2+/gtE neurites but appeared to be accelerated in 
cut Nmnat2gtBay/gtE neurites (Fig. 5E). Whilst Nmnat2gtBay/gtE neurites did appear slightly less 
healthy at the time of transection, possibly reflecting that the distal ends of a few cannot be 
supported effectively with that level of NMNAT2 expression, the relative rate of degeneration 
was still found to be accelerated by around one hour (Fig. 5F). Reducing NMNAT2 levels can 
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thus accelerate Wallerian degeneration but only when starting levels are below a certain 
threshold. 
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DISCUSSION 
The findings presented here indicate that constitutively low NMNAT2 levels in mice are not 
phenotypically neutral, at least below a threshold level, but can significantly affect the 
development, survival and vulnerability of peripheral axons to the extent that axon loss occurs 
and specific behaviors are impaired. Whilst these changes are only evident in mice when 
steady-state levels are substantially below a theoretical heterozygous level of 50% of normal 
expression, a more modest reduction in NMNAT2 functionality in humans could have a similar 
outcome given their longer axons, extended lifespan and greater exposure to environmental 
stresses. Indeed, the human NMNAT2 gene shows an unusually low population frequency of 
splicing and frameshift mutations predicted to result in heterozygous loss-of-function, at least 
within the Exome Aggregation Consortium (ExAC; http://exac.broadinstitute.org) (21) which 
excludes individuals with pediatric disease. The probability of loss-of-function intolerance 
(pLI) of 0.94 places NMNAT2 within the top decile of human genes for intolerance of 
haploinsufficiency (22) implying that heterozygosity in humans has a significantly worse 
outcome than in mice. However, this will need to be confirmed in future studies. Nevertheless, 
the reported 50-fold or more variation in NMNAT2 mRNA levels in human post-mortem brains 
(11), presumably resulting from natural variation in gene regulation, raises the real possibility 
that NMNAT2 functionality in a significant number of individuals will be reduced to a level at 
which susceptibility of certain axon populations to age-related, toxin-induced or disease-
dependent stresses is increased thereby predisposing them to peripheral axonopathy. The fact 
that Nmnat2gtBay/gtE neurites are more susceptible to vincristine toxicity in vitro suggests that 
chemotherapy-induced peripheral neuropathy, which has already been shown to involve a 
Wallerian-like process in vivo (23), is one specific human disorder where variation in 
NMNAT2 levels could influence outcome.  
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 An early deficiency of some small caliber myelinated sensory axons in the L3 dorsal roots 
of Nmnat2gtBay/gtE compound heterozygote mice suggests that a subset of A fiber DRG neurons 
are particularly sensitive to low NMNAT2 levels. Proximity of the axon loss to the DRG 
suggests that their neurons are probably also absent and a pattern of compromised axon 
outgrowth precipitating loss of viability due to a lack of trophic support during embryonic or 
early postnatal development is likely. The lack of any clear neurite outgrowth defect in 
Nmnat2gtBay/gtE DRG explant cultures appears to contradict this model, but compromised 
outgrowth from the subset of affected A fiber neurons could easily be masked by normal 
outgrowth from the other, more abundant DRG neurons. Alternatively, affected A fiber DRG 
neurons may already be absent by E13.5 or their neurites may not extend far enough in culture 
for a defect of longer in vivo axons to be seen. However, the retarded neurite outgrowth seen 
in SCG neuron cultures indicates that sub-heterozygous NMNAT2 levels can be limiting in 
some contexts. In contrast, low NMNAT2 levels seem to only affect motor axon survival late 
in life, and likely only from 18 months onwards (an absence of sensory axons is seemingly able 
to fully account for the deficiency of myelinated tibial nerve axons up to this age). In this 
respect, the previously observed reduction in anterograde trafficking of NMNAT2 in sciatic 
nerve axons between 18 and 24 months (24) could cause NMNAT2 levels to decline even 
further in Nmnat2gtBay/gtE distal axons such that they consequently drop below the critical 
threshold for motor axon survival which precipitates dying-back degeneration. The presence 
of an apparent regenerative response suggests that the motor neurons themselves remain viable, 
at least in the short-term. 
 Our findings thus reveal significant heterogeneity not only between, but also within, 
different peripheral neuron populations with respect to the sensitivity of their axons to low 
NMNAT2 levels. Natural variation in expression of NMNAT2 between different neuron types 
or sub-types and/or an ability to maintain its supply into axons is one possible explanation. 
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Alternatively, variation in axonal levels of other key molecules in the Wallerian degeneration 
pathway could determine survival, even when NMNAT2 levels are equivalent. However, 
currently-available NMNAT2 antibodies lack the sensitivity and/or specificity for reliable, 
quantitative immunostaining and/or immunoblotting of nerve tissue meaning this cannot yet 
be determined. 
 Silencing of a single Nmnat2gtE allele in primary SCG neuron cultures is sufficient to cause 
neurite degeneration (3), so the lack of peripheral axon loss in Nmnat2+/gtE single heterozygote 
mice, even in old age, further highlights the apparent discrepancy between the effects of 
constitutive or acute reduction of NMNAT2 levels. We have previously argued that 
compensatory changes during early development may partially reduce the dependence on 
NMNAT2 thereby lowering the NMNAT level required for maintaining axon health (3). Such 
changes have yet to be identified but do not appear to involve altered expression of other key 
enzymes in the NAD-biosynthetic pathway (3). Other than altering the NMNAT2-dependent 
survival threshold for axons, invoking compensatory changes as a response to reduced 
NMNAT2 does not alter our interpretation of the main findings reported here, but it could 
provide an explanation for why Wallerian degeneration is only accelerated in Nmnat2gtBay/gtE 
compound heterozygote neurites and not in Nmnat2+/gtE single heterozygote neurites. Based on 
a model of Wallerian degeneration in which rapid NMNAT2 loss in transected axons, as a 
result of natural turnover, is an early trigger for degeneration (4), the latent phase before frank 
degeneration would be predicted to be accelerated by one half-life of NMNAT2 turnover, 
around 40 minutes (25), in cut Nmnat2gtE neurites and by two half-lives in cut Nmnat2gtBay/gtE 
neurites. However, compensatory changes could, up to a point, make the duration of the latent 
phase dependent on other factors such that it is only shortened when NMNAT2 levels drop 
below a lower threshold to become limiting. 
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 Whilst it is easy to correlate motor axon changes to the declining motor performance seen 
in old Nmnat2gtBay/gtE mice, the link between the early deficiency of a substantial proportion of 
A fibers and sensory behaviors in the mice is more complicated given the varying 
contributions of different sensory fiber types both to peripheral thermosensation and 
mechanosensation (26, 27). Some A fibers are involved in thermosensation, so loss of this 
type likely contributes to the reduced temperature discrimination seen in Nmnat2gtBay/gtE mice, 
although the majority are also involved in mechanosensation (28, 29). The unaltered response 
of Nmnat2gtBay/gtE mice to non-painful pressure is therefore intriguing. Our findings should thus 
act as a useful starting point for future, more focused studies of sensory perception in these 
mice, including an assessment of unmyelinated C fibers. 
 Whilst this study was focused solely on peripheral axons, it will be important to determine 
whether survival of specific populations of CNS axons is also compromised when NMNAT2 
levels are low. Peripheral axon defects caused by low NMNAT2 appear largely restricted to 
Nmnat2gtBay/gtE compound heterozygote mice with sub-heterozygous expression, at least within 
the confines of the parameters assessed here, but there is already a suggestion that some CNS 
neuron / axon populations might be affected even in Nmnat2+/gtE single heterozygotes (11, 14). 
It will thus be interesting to establish whether these specific populations are more severely 
affected in Nmnat2gtBay/gtE mice and/or whether CNS axon defects are generally more 
widespread. Furthermore, it will be important to determine whether any central pathways also 
contribute to the sensory or motor defects identified in Nmnat2gtBay/gtE mice in this study. 
 In summary, we have shown that sub-heterozygous NMNAT2 levels can influence 
peripheral axon development and survival in mice in both an age-dependent and neuron type-
dependent manner and that this correlates with behavioral changes. Crucially, as discussed 
above, reduced NMNAT2 function could have a greater impact in longer and more long-lived 
human axons. The wide range of NMNAT2 mRNA expression reported in humans, together 
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with the possibility that some natural coding variants might also impair NMNAT2 activity, 
already suggests this is likely to be clinically relevant, especially during ageing when 
NMNAT2 axonal transport declines (24), or in pathological situations where its transport or 
synthesis is further perturbed. Intrinsic variation in NMNAT2 expression and/or function in 
humans could thus underlie differential responses to chemotherapy, diabetes or any other 
stresses that promote Wallerian-like axon degeneration.  
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MATERIALS AND METHODS 
 
Mouse breeding, genotyping and usage 
Animal work was approved by the Babraham Institute Animal Welfare, Experimentation and 
Ethics Committee and was performed in accordance with the Animals (Scientific Procedures) 
Act, 1986, under Project License PPL 70/7620. Generation of mice bearing the Nmnat2gtE and 
Nmnat2gtBay gene trap alleles and crosses to generate Nmnat2gtBay/gtE compound heterozygotes 
have been described (3, 15). 
 We performed separate duplex PCR to assess transmission of the two gene trap alleles 
using the following primers: primers 5'-gctggcctaggtggtgatttgc-3' (forward for wild-type), 5'-
agtcatagacactagacaatcgg-3' (forward for gene trap), and 5'-actgggatgcacgagaccctgc-3' (reverse 
for both) to amplify a 552-bp product from the Nmnat2gtE gene trap allele and a 491-bp product 
from the corresponding wild-type locus with primer annealing at 60°C and extension at 68°C 
(3); and primers 5'-, 5'-aggaagcagggagaggcag-3' (reverse for wild-type) and 5'-
tgcaaggcgattaagttgggtaacg-3' (reverse for gene trap), and gagccacagactagtgactggttg-3' (forward 
for both) to amplify a 206-bp product from the Nmnat2gtBay gene trap allele and a 310-bp 
product from the corresponding wild-type locus with primer annealing and extension both at 
65°C. 
 All mice used in this work were from the same breeding colony and littermates were used 
wherever possible. Female mice were preferentially used in long-term ageing studies to avoid 
having to house lone males for long periods, although axon counts at 24 months were 
confirmed in at least one male of each genotype. 
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Reverse transcriptase-PCR (RT-PCR) 
Semi-quantitative endpoint RT-PCR was used to assess Nmnat2 mRNA expression in whole 
mouse brain using the same primers and conditions as described previously (3). 
 
Analysis of myelinated axons in tibial nerves and L3 roots 
The lower leg and vertebral columns of mice were fixed in 4% paraformaldehyde in 0.1M PBS 
(p.H. 7.4). For tibial nerves, blocks of calf muscles from mid-way between knee and ankle of 
the lower leg were cryosectioned at 20 µm such that the sections contained transverse sections 
of the nerve. For L3 dorsal and ventral roots, the L3 DRG was dissected out of the vertebral 
column along with its associated roots and mixed nerve and cryosectioned at 20 µm to produce 
transverse sections of the roots less than 1 mm from the DRG itself. Sections were then stained 
with FluoroMyelin™ Red (Life Technologies) according to the manufacturer’s instructions. 
The tibial nerve was easily identified based on its size and position relative to different muscle 
groups in the calf. 
 Images of tibial nerves and L3 roots were captured on an Olympus FV1000 point scanning 
confocal microscope imaging system (40x objective). Axon counts (inferred from numbers of 
myelin sheaths), nerve cross-sectional area and axon diameters were determined using tools in 
ImageJ/Fiji software . Axon counts were performed blind. Axon diameter was measured as the 
maximum internal diameter of the myelin sheath for all axons in adjacent 500 µm2 grid boxes 
running diagonally across the nerve cross-section to randomly sample at least 145 axons from 
each nerve analyzed. Axon diameter and nerve cross-sectional area were only measured for 
nerves where a true transverse section was obtained. 
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Mouse behavior tests 
Dynamic Plantar Aesthesiometer. Touch sensitivity was assessed using a Dynamic Plantar 
Aesthesiometer (Ugo Basile, Varese, Italy). The apparatus automatically recorded the latency 
and force at the time of the paw withdrawal reflex in response to increasing pressure of a steel 
probe (0.5 mm diameter) applied to the plantar surface of either hindpaw of the mice. Mice 
were familiarized to the apparatus for 1 h prior to testing. Probe force increased up to 5 g over 
an initial 10 s period and this was maintained for a further 20 s for a maximum trial time of 30 
s. The average latency and force at paw withdrawal was calculated from five valid trials for 
each mouse (trials where paw withdrawal occurred due to spontaneous movements were 
discounted). 
Two-place Temperature Preference. Thermal preference was tested using a two-place thermal 
place preference apparatus (Bioseb, Vitrolles, France). Mice were placed in a run consisting of 
adjacent plates that can be set at different temperatures. In tests mice were offered a choice 
between a comfortable temperature of 30°C on one plate and a variable test temperature on the 
other. Mice were able to freely move between the two plates in the run and the time spent on 
each plate during a 5 min period was recorded automatically. Each mouse was tested for 
avoidance of warm and cold temperatures in two separate sessions on consecutive days. 
Duplicate trials were run sequentially for each test temperature, switching the test and reference 
plates, to control for positional preferences (independent of temperature) or memory of 
previous trials. Mice stayed in the runs between trials as plates cooled/warmed at their 
maximum rate. The percentage time spent at each test temperature was averaged from the two 
plate orientations for that temperature. For the 30°C/30°C preference each plate was considered 
the test plate for one half of the 5 min trial period to control for positional preferences. There 
was no statistically-significant difference between genotypes in overall distance travelled or 
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number of transitions between plates in the 30°C/30°C preference trial ruling out locomotor 
activity as a confounding factor in the changes in avoidance seen at other temperatures. 
Accelerating Rotarod. Locomotor performance and balance were tested on an accelerating 
Rotarod (Ugo Basile, Model 7650, Varese, Italy). Mice were familiarized with the apparatus 
(two 5 min runs at 10 rpm) one day before the first test age. Mice were tested at 3 month 
intervals from 6 to 24 months of age. The majority of the mice were tested at all ages, although 
small numbers of mice were added at later ages to supplement natural losses. At each age mice 
performed three 5 min trials, where rotation increased from 3 to 30 rpm, separated by 30 min 
rests. The latency to fall (max 300 s) was recorded only for involuntary falls. Mice dismounting 
voluntarily were put back on the apparatus once but were excluded from the analysis if this 
was repeated. Best trial performance was used for statistical analyses. 
 
Primary neuronal explant cultures 
Superior cervical ganglia (SCG) were dissected from postnatal day 0-2 mouse pups and dorsal 
root ganglia (DRG) were dissected from E13.5-E14.5 mouse embryos and cultured essentially 
as described previously (3). Images of neurites were captured using a Soft Imaging Systems 
(SIS) F-View camera linked on an Olympus IX81 inverted microscope. For each of the 
analyses described below the effects of manipulations were recorded from both SCGs from 
each mouse pup and multiple DRGs from each mouse embryo and these were averaged to give 
an animal average. Animal averages were then used to generate genotype means. 
 Radial neurite outgrowth from SCG and DRG ganglia was assessed from low 
magnification (4x objective) phase contrast images on each specified day after plating. Where 
neurite outgrowth extended beyond a single field two overlapping images were combined. Two 
measurements of radial outgrowth were recorded for each ganglion (maximal outgrowth from 
ganglia to the ends of the most distal neurites) on each day to give a ganglion average. 
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 Vincristine sulphate (Sigma), dissolved in DMSO, was added to SCG cultures every day 
in fresh media at a final concentration of 1 nM from DIV5 onwards. Phase contrast images of 
the same field of neurites were captured (20x objective) at 0, 3 and 6 days after vincristine 
addition. The Degeneration Index of distal neurites was calculated using ImageJ essentially as 
described previously (30), except that a size range of 10-350 pixels was used for calculating 
the area constituting degenerated axon fragments in the 1376 x 1032 pixel images. 
 Neurite transection assays were performed in the same SCG cultures used for the 
assessment of neurite outgrowth. Neurites were cut at DIV8 with a scalpel at a point roughly 
midway between the ganglion and their distal ends. Phase contrast images of the same field of 
cut neurites were captured (20x objective) at 1-2 h intervals after cut as indicated. The 
Degeneration Index of cut neurites was calculated as above except that the range of pixels used 
for calculating the area constituting degenerated axon fragments was adjusted to account for 
differing neurite densities between dishes. A size range of 10-350 pixels was used for fields 
with dense neurites and 10-200 pixels was used for fields with sparse neurites (in 1376 x 1032 
pixel images captured using the 20x objective) with the same settings being applied to the same 
field of neurites at all timepoints. 
 
Statistical analyses. 
The numbers of samples and/or the age, sex and numbers of mice used in each individual 
experiment are described in the relevant section of the main text or figure legend. Statistical 
testing of data was performed using Prism (GraphPad Software Inc., La Jolla, USA). The 
appropriate tests used are described in the Figure legends. A p value < 0.05 was considered 
significant.  
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LEGENDS TO FIGURES  
 
Figure 1. Mice with graded levels of Nmnat2 expression are viable and overtly normal. 
(A) Genotype frequencies of viable offspring from crosses between Nmnat2+/gtE and 
Nmnat2+/gtBay mice. The observed birth frequencies are not significantly different from 
expected frequencies: 2 = 0.583, d.f. = 3, p = 0.9004. (B) Body weights of male and female 
mice of the indicated genotypes at 5-8 months and female mice at 21-24 months. Individual 
mouse weights with means ±SEM are plotted. n.s. = not significant [p > 0.05], separate one-
way ANOVA for males and females at each age with Dunnett’s multiple comparison tests 
(relative to wild-types). (C) Quantification of endpoint RT-PCR analysis of relative Nmnat2 
mRNA levels in the brains of 6 month wild-type, Nmnat2+/gtBay, Nmnat2+/gtE and Nmnat2gtBay/gtE 
mice. Data are presented as the mean percentage ± SEM of wild-type levels after normalization 
to Actb mRNA levels. * p < 0.05, ** p <0.01 and *** p < 0.001, one-way ANOVA with 
Tukey’s multiple comparison tests (n = 4 sets of each genotype). 
 
Figure 2. Early deficiency and later loss of myelinated tibial nerve axons in Nmnat2 
compound heterozygote mice. 
(A) Numbers of myelinated axons in tibial nerves of mice of the indicated genotypes and ages 
(n = 4-5 per genotype at each age). Individual values and means ±SEM are plotted. n.s. = not 
significant [p > 0.05] and *** p < 0.001, separate one-way ANOVA for each age with Tukey’s 
multiple comparison tests. (B) Numbers of myelinated axons in tibial nerves of mice of the 
indicated genotypes and ages (n = 4-5 per genotype at each age). Individual values and means 
±SEM are plotted. n.s. = not significant [p > 0.05] and *** p < 0.001, two-way ANOVA with 
Bonferroni’s multiple comparison tests for effects within genotypes (selected results shown). 
(C) Complete tibial nerve cross-sections stained with FluoroMyelin™ Red from mice of the 
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indicated genotypes and ages (representative of n = 4-5 per genotype). (D) Plots of axon counts, 
nerve cross-sectional area and axon density for tibial nerves from Nmnat2gtBay/gtE compound 
heterozygote mice at the indicated ages as a percentage of that in wild-type tibial nerves (n = 
4-5 nerves per genotype at each age). 
 
Figure 3. Early deficiency of myelinated axons in L3 dorsal root and later changes to 
myelinated axons in L3 ventral root in Nmnat2 compound heterozygote mice. 
(A) Numbers of myelinated axons in L3 dorsal roots of mice of the indicated genotypes and 
ages (n = 4-5 per genotype at each age). Individual values and means ±SEM are plotted. n.s. = 
not significant [p > 0.05] and *** p < 0.001, two-way ANOVA with Bonferroni’s multiple 
comparison tests. (B) Distribution of axon diameters in 6 month old wild-type and 
Nmnat2gtBay/gtE compound heterozygote L3 dorsal roots. Mean distribution ±SEM is plotted for 
total numbers of axons in three roots of each genotype calculated from a random sample of at 
least 145 axons per root. n.s. = not significant [p > 0.05] and *** p < 0.001, two-way ANOVA 
with Sidak’s multiple comparisons for between genotype effects. (C) Cross-sections of L3 
dorsal root myelinated axons stained with FluoroMyelin™ Red from 24 month old mice of the 
indicated genotypes (representative of n = 5 per genotype). (D) Numbers of myelinated axons 
in L3 ventral roots of mice of the indicated genotypes and ages (n = 4-5 per genotype at each 
age). Individual values and means ±SEM are plotted. n.s. = not significant [p > 0.05] and * p 
< 0.05, two-way ANOVA with Bonferroni’s multiple comparison tests. (E) Cross-sections of 
L3 ventral root myelinated axons stained with FluoroMyelin™ Red from mice of the indicated 
genotypes and ages (representative of n = 4-5 per genotype). Axons with thin myelin sheaths, 
resembling regenerating axons, are labelled with asterisks. (F) Number of myelinated axons in 
L3 ventral roots of 24 month old mice of the indicated genotypes (n = 5 per genotype) grouped 
based on the status of their myelin sheaths. Axons with normal thickness myelin were classed 
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as “healthy”, those with invaginations, evaginations or wide incisures as “abnormal” and those 
with thin myelin (relative to axon diameter) as “thin”. Individual values and means ±SEM are 
plotted. n.s. = not significant [p > 0.05], * p < 0.05 and ** p < 0.01, individual t tests for each 
class of axons. 
 
Figure 4. Touch sensitivity is normal in Nmnat2gtBay/gtE compound heterozygote but 
thermal perception and Rotarod performance are both altered. 
(A) Force at paw withdrawal (left graph) and latency to paw withdrawal (right graph) for 6-9 
month old male mice of the indicated genotypes (n = 9-12 per genotype) in the dynamic plantar 
aesthesiomter test. Individual values and means ±SEM are plotted. n.s. = not significant [p > 
0.05], one-way ANOVA with Tukey’s multiple comparison tests. (B) Percentage time spent at 
the test temperature for 6-9 month old male mice of the indicated genotypes (n = 9-12 per 
genotype) in the two-place temperature preference test (control plate at 30°C). Means ±SEM 
are plotted. n.s. = not significant [p > 0.05], separate one-way ANOVA for each test 
temperature with Tukey’s multiple comparison tests. (C and D) Latency to fall for female mice 
of the indicated genotypes in a longitudinal Rotarod analysis between the ages of 6 and 24 
months. Means ±SEM for the same data are plotted in alternative ways to highlight different 
statistical differences: n.s. = not significant [p > 0.05], ** p < 0.01 and *** p < 0.001, two-way 
ANOVA with Dunnett’s multiple comparison tests for age effects (relative to 6 months) within 
each genotype in (C); n.s. = not significant [p > 0.05] and ** p < 0.01, two-way ANOVA with 
Tukey’s multiple comparison tests for effects between genotypes at each age in (D). (E) Body 
weights of mice at each test age in the Rotarod analysis described in (C and D). Means ±SEM 
are plotted. There is no statistically-significant difference in body weight between genotypes 
at any age (two-way ANOVA with Tukey’s multiple comparison tests). 
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Figure 5. Altered outgrowth and survival of Nmnat2gtBay/gtE compound heterozygote SCG 
neurites. 
(A) Representative images of neurite outgrowth at DIV5 in SCG explant cultures of the 
indicated genotypes. (B) Quantification of neurite outgrowth in SCG explant cultures of the 
indicated genotypes between DIV0 and DIV7. Mean outgrowth ±SEM is plotted for ganglia 
from n = 3-4 embryos per genotype. n.s. = not significant [p > 0.05], ** p < 0.01 and *** p < 
0.001, two-way ANOVA with Tukey’s multiple comparisons for between genotype effects at 
each timepoint. (C) Representative images of neurites in SCG explant cultures of the indicated 
genotypes after 144 h of daily 1 nM vincristine treatment or without treatment. (D) 
Quantification of the degeneration index (DI) of neurites in SCG explant cultures of the 
indicated genotypes at various times after starting daily 1 nM vincristine treatment or without 
treatment. Mean DI ±SEM is plotted for ganglia from n = 3 embryos per genotype. n.s. = not 
significant [p > 0.05], ** p < 0.01 and *** p < 0.001, two-way ANOVA with Tukey’s multiple 
comparisons for between genotype effects at each timepoint. (E) Representative images of 
transected SCG neurites of the indicated genotypes at the time of cut (0h cut) and 4 h after cut 
(4h cut). (F) Quantification of the degeneration index (DI) of transected SCG neurites of the 
indicated genotypes at various times after cut. Mean DI ±SEM (left graph) and mean change 
in DI (right graph) are plotted for ganglia from n = 3-4 embryos per genotype. n.s. = not 
significant [p > 0.05], * p < 0.05, ** p < 0.01 and *** p < 0.001, two-way ANOVA with 
Tukey’s multiple comparisons for between genotype effects at each timepoint. 
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ABBREVIATIONS 
NMNAT; nicotinamide mononucleotide adenylyltransferase 
WldS ; slow Wallerian degeneration 
SARM1; sterile alpha and TIR motif-containing protein 1 
NAD; nicotinamide adenine dinucleotide 
NMN; nicotinamide mononucleotide 
PNS; peripheral nervous system 
CNS; central nervous system 
SNP; single nucleotide polymorphism 
DRG; dorsal root ganglion 
SCG; superior cervical ganglion 
DIV; days in vitro 
 





